SpinalCyte earns international patent for biologic product: 3 insights

Written by Shayna Korol | January 08, 2019 | Print  |

SpinalCyte received a new Australian patent related to its fibroblast technology.

Here are three things to know:

1. CybroCell now comprises 36 U.S. and foreign issued patents with 40 pending.

2. The new patent involves differentiating human dermal fibroblast into chondrocyte-like cells by exposing them to a specific environment of growth factors, hypoxia, hydrostatic pressure and shear stress.

3. CybroCell is an off-the-shelf allogenic human dermal fibroblast product designed to treat degenerative disc disease.

More articles on biologics:
DiscGenics' cell therapy passes safety review of first-in-human trial: 5 things to know
3 things to know about JRF Ortho
StemCyte gets FDA green light to continue studying spinal cord injury treatment stem cells: 5 takeaways

© Copyright ASC COMMUNICATIONS 2019. Interested in LINKING to or REPRINTING this content? View our policies here.

Top 40 Articles from the Past 6 Months